On the contrary, PCa patients with more aggressive disease, as those HLA-A*02:01 genotyped, should immediately start appropriate treatment schemes to delay metastases (including ADT, second-line anti-androgens, and/or chemotherapy) according to other risk-indicative clinicopathological characteristics. The gene discussed is HLA-A; the disease is posterior cortical atrophy.